Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.
about
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapiesAdenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapyEffect of the antipsychotic agent amisulpride on glucose lowering and insulin secretionOptimal Pharmacologic Treatment Strategies in Obesity and Type 2 DiabetesAmerican Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.Bromocriptine in type 2 diabetes mellitusThe effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study.Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.Mitochondrial dysregulation in the pathogenesis of diabetes: potential for mitochondrial biogenesis-mediated interventions.Hypothyroidism stimulates D2 receptor-mediated breathing in response to acute hypoxia and alters D2 receptors levels in carotid bodies and brainDoes Twice-weekly Cabergoline Improve Anthropometrical and Biochemical Profiles in Prediabetes? A Randomized Double-blind Clinical Trial Pilot Study.Novel Agents for the Treatment of Type 2 Diabetes.Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies.Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients.Association Between Prolactin and Incidence of Cardiovascular Risk Factors in the Framingham Heart StudyHistory of current non-insulin medications for diabetes mellitus.Mechanisms of current therapies for diabetes mellitus type 2A comparison of D2 receptor specific binding in obese and normal-weight individuals using PET with (N-[(11)C]methyl)benperidol.Bromocriptine, a Dopamine (d2) Receptor Agonist, Used Alone and in Combination with Glipizide in Sub-Therapeutic Doses to Ameliorate HyperglycaemiaInteractome-transcriptome analysis discovers signatures complementary to GWAS Loci of Type 2 DiabetesPlasma metabolomic profiles in association with type 2 diabetes risk and prevalence in Chinese adults.Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated.Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: a randomized open labeled phase IV clinical trial.Why does quick-release bromocriptine decrease cardiac events?Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR.The impact of current and novel anti-diabetic therapies on cardiovascular risk.Advances in pharmacologic therapies for type 2 diabetes.Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR.Treating the obese diabetic.Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors.Brain areas and pathways in the regulation of glucose metabolism.Overview of food products and dietary constituents with antidiabetic properties and their putative mechanisms of action: a natural approach to complement pharmacotherapy in the management of diabetes.Pharmacotherapy considerations in diabetes and obesity: setting patients up for success.Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.Neurotransmitters and Neuropeptides: New Players in the Control of Islet of Langerhans' Cell Mass and Function.The role of prolactin in andrology: what is new?Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.
P2860
Q22241288-D99D1BB0-47C2-40C7-BA2E-4C3602D6B7BFQ26740253-BD85FDC5-5257-4BD0-BA5B-269B7548EBE9Q26744317-DCCDA638-1803-40A3-99EF-11F379AF20D6Q28068120-02A64709-9B6B-45E5-AD0B-79F432F9EEB8Q28252428-CE423599-D046-4438-A6B4-8E9713E238EAQ30377441-F5FDA155-1616-4C23-9D80-E8279CEAEDCEQ34081331-89E8CDAD-7382-4F11-A9BC-7C180D54DD1FQ35153082-05E5B4CC-18F9-44CA-864B-969618B04F8CQ35546563-13EE5E43-2B15-4108-90D6-3707A16E6A9CQ35594537-A239DCE8-9210-4FCB-8206-6A153EBE67A7Q35607344-24A30CFE-AD6A-449F-8347-BBF62369A9CDQ35624071-CE312863-5629-4FC2-8862-169C9D1D1D50Q35843293-0766A110-31B7-454C-AA55-141984ABFC26Q35910421-07165EE1-E524-4FF7-AA0E-E89E81B5DA59Q36523427-38E5E6B7-C40B-4B9B-A1DC-9866D9C9AF49Q36560960-84D7B159-821C-4B78-816F-8E7D3515CA9EQ36714142-F84023D5-0977-4C11-9B3F-019A7C9DAC5CQ37021310-017B0B34-D9AC-46B6-9386-EEDB764C97E8Q37180829-57401183-9948-4B11-8852-AEA32B370F77Q37185341-05B9A9DF-1332-46BF-8EF3-D81F92857A3CQ37258822-AB37F1EB-1956-44BE-8613-0E7F81C0F8C0Q37345367-08D6C320-E713-4981-9709-FFEDE9AB7BDEQ37403973-3B0BD832-861A-4465-9FA1-1A3BB7861EB5Q37509313-02B62401-20DF-4460-8CCF-91ED1BF0FDC7Q37551483-D9CC9001-1553-4D1A-862C-8AE7156A7223Q37875221-708B0E91-3BB2-4914-9944-37EBF60C88DAQ38055296-F5940AB3-3B3C-4FD6-9C94-1478214F463AQ38062033-5A1B758F-46E2-43C3-8351-12331C3A1638Q38072616-14D1D8E9-932F-4C7C-A0F2-F202B91ECC90Q38085727-DA592A7A-4F34-4B2B-8F13-B3985BB8338CQ38087696-87C90E82-C175-454B-8650-1278310AA31FQ38113095-DDA3192D-2FF3-426B-A2CF-094A12B70CD2Q38113101-C252C8D8-0571-4130-BBB9-B7EA646DB0C1Q38126466-3371F942-ACB4-48E3-8D03-6E509C805F35Q38128788-31A68005-BFB6-42C4-9F26-F27C79E1E95BQ38200829-C29F0A09-5D88-4F53-8379-EF9FA9852B22Q38378534-E1AFDA51-F6CF-430F-B6EF-C7DC2973CA2FQ38579025-9F3853A8-A647-4BD6-9EAD-98548426379DQ38626657-D7B7CF49-9577-4F37-8295-E64BA4E5D82FQ38866310-9E2E2E4A-386D-46FA-A3E5-95DC52F2AF8B
P2860
Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.
@ast
Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.
@en
Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.
@nl
type
label
Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.
@ast
Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.
@en
Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.
@nl
prefLabel
Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.
@ast
Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.
@en
Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.
@nl
P2860
P31
P921
P356
P1433
P1476
Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.
@en
P2093
Ralph A Defronzo
P2860
P304
P356
10.2337/DC11-0064
P407
P5008
P577
2011-04-01T00:00:00Z